Table 2. Univariate Cox regression analysis of OS and CSS in the training cohort.
| Variable | OS | CSS | |||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | ||
| Age (years) | |||||||
| 20–40 | 1 | 1 | |||||
| 41–60 | 0.922 | 0.779–1.092 | 0.347 | 0.945 | 0.790–1.130 | 0.534 | |
| 61–80 | 0.854 | 0.719–1.014 | 0.071 | 0.868 | 0.724–1.042 | 0.128 | |
| Race | |||||||
| White | 1 | 1 | |||||
| Black | 1.076 | 0.941–1.231 | 0.282 | 1.061 | 0.921–1.222 | 0.413 | |
| Others | 1.114 | 0.934–1.329 | 0.229 | 1.075 | 0.891–1.298 | 0.447 | |
| Laterality | |||||||
| Left | 1 | 1 | |||||
| Right | 1.043 | 0.946–1.150 | 0.397 | 1.04 | 0.939–1.152 | 0.454 | |
| Tumor grade | |||||||
| I | 1 | 1 | |||||
| II | 1.299 | 1.065–1.585 | 0.01 | 1.404 | 1.130–1.745 | 0.002 | |
| III/IV | 1.952 | 1.605–2.375 | <0.001 | 2.155 | 1.739–2.670 | <0.001 | |
| T stage | |||||||
| T1 | 1 | 1 | |||||
| T2 | 1.002 | 0.847–1.187 | 0.978 | 0.97 | 0.813–1.157 | 0.733 | |
| T3 | 1.205 | 1.005–1.445 | 0.044 | 1.2 | 0.993–1.451 | 0.06 | |
| T4 | 1.394 | 1.176–1.651 | <0.001 | 1.397 | 1.170–1.667 | <0.001 | |
| N stage | |||||||
| N0 | 1 | 1 | |||||
| N1 | 0.99 | 0.872–1.124 | 0.878 | 0.998 | 0.872–1.141 | 0.972 | |
| N2 | 0.902 | 0.762–1.069 | 0.234 | 0.899 | 0.751–1.077 | 0.248 | |
| N3 | 1.003 | 0.858–1.173 | 0.967 | 1.042 | 0.884–1.227 | 0.627 | |
| Histological type | |||||||
| Ductal | 1 | 1 | |||||
| Lobular | 0.959 | 0.817–1.125 | 0.606 | 0.964 | 0.815–1.140 | 0.67 | |
| Mixed ductal and lobular | 0.857 | 0.684–1.074 | 0.181 | 0.859 | 0.678–1.088 | 0.208 | |
| Others | 1.642 | 1.349–1.999 | <0.001 | 1.705 | 1.392–2.088 | <0.001 | |
| Tumor size (cm) | |||||||
| <5 | 1 | 1 | |||||
| 5–10 | 1.235 | 1.114–1.369 | <0.001 | 1.263 | 1.134–1.408 | <0.001 | |
| >10 | 1.836 | 1.521–2.215 | <0.001 | 1.954 | 1.613–2.368 | <0.001 | |
| Tumor subtype | |||||||
| Luminal A | 1 | 1 | |||||
| Luminal B | 0.883 | 0.767–1.017 | 0.085 | 0.865 | 0.746–1.004 | 0.056 | |
| HER2+ | 1.175 | 0.959–1.439 | 0.119 | 1.168 | 0.944–1.444 | 0.153 | |
| Triple-negative | 3.366 | 2.931–3.866 | <0.001 | 3.482 | 3.013–4.023 | <0.001 | |
| Surgery | |||||||
| Yes | 1 | 1 | |||||
| No | 1.842 | 1.658–2.047 | <0.001 | 1.814 | 1.624–2.026 | <0.001 | |
| Radiotherapy | |||||||
| Yes | 1 | 1 | |||||
| No | 0.996 | 0.903–1.098 | 0.928 | 0.959 | 0.865–1.063 | 0.424 | |
| Chemotherapy | |||||||
| Yes | 1 | 1 | |||||
| No | 1.269 | 1.150–1.401 | <0.001 | 1.238 | 1.116–1.374 | <0.001 | |
| Number of metastatic organs except bone | |||||||
| 0 | 1 | 1 | |||||
| 1 | 1.678 | 1.504–1.873 | <0.001 | 1.735 | 1.547–1.947 | <0.001 | |
| ≥2 | 3.078 | 2.676–3.541 | <0.001 | 3.24 | 2.798–3.751 | <0.001 | |
Grade I: well differentiated; Grade II: moderately differentiated; Grade III: poorly differentiated; Grade IV: undifferentiated anaplastic. OS, overall survival; CSS, cancer-specific survival.